UPDATE 20 OCTOBER: POSTPONED INDEFINETELY
In view of the current developments and advice regarding COVID-19, we unfortunately had to decide to reschedule the Symposium “ Translating Science into Innovative Treatment" of 27 October 2020 (4.30 - 6.00 PM) to a date yet to be determined. The Symposium was planned as a hybrid event in UMCG with both physical and online guests and speakers. Current developments do not make it possible to organize the event in this way.
For us as organization committee, but especially for you as one of the over 180 interested attendees, this is very unfortunate and requires flexibility. We hope to welcome you digitally or physically on a date yet to be determined.
UPDATE SEPTEMBER: NEW DATE 27 OCTOBER
Update on Symposium : The symposium ‘Translating science into innovative treatment’ has been rescheduled to October 27th. Due to Corona the original symposium had to be postponed and because there was great interest to participate (> 150 sign ups), we decided to include a digital format for the rescheduled event on Ocotber 27th. Up to a maximum of 25 people can physically attend, an unlimited number can participate online.
Translating science into innovative treatment
Every day, scientific innovations occur at the UMCG, University of Groningen and Hanze University as well as at life sciences companies in our region. Innovations that have the potential to evolve to new innovative treatments, but may never reach that stage because the innovator doesn’t know about the possibilities or how to get there.
To support innovators to translate their science into innovative treatment, an initiative was launched offering both financial funding (Pharma Connect Capital) and industrial-style support (Pharma Portal) to scientists who have an idea on developing their innovation towards new pharmaceutical treatments or diagnostic tools.
You are invited
As a scientist with an ambition in this field, you are invited to attend the Symposium on 27 October. Request to register via the form on this page.
At the Symposium you can learn from a.o. Nobel Prize laureate Ben Feringa on how your ambition can gain momentum with proper development and financial support.
Program
- Chaired by: Pieter de Graeff, CBG
- Introduction: Marian Joëls, member Board of Directors UMCG
- Ben Feringa, Co-founder & David Kijlstra, Co-founder & CEO Lumento Therapeutics: Shining light on the development of a new class of cancer therapeutics
- Reinier Schwietert, CEO & Marieke Bolling, Dermatologist UMCG Philae Pharmaceuticals: Much-needed treatment for Epidermolysis Bullosa (EB)
- Jan Hendriks, Fund Manager Pharma Connect Capital: Financial investment in early stage drug development plans
- Martin Smit, Chairman Board Pharma Portal: Creating feasible plans ready for investment
- Panel discussion
